EUGLOREH project
THE STATUS OF HEALTH IN THE EUROPEAN UNION:
TOWARDS A HEALTHIER EUROPE

FULL REPORT

PART I - THE CONTEXT FOR HEALTH

2.   THE CHANGING CONTEXT FOR HEALTH IN THE EUROPEAN UNION

2.10 Technological developments

2.10.2. Nanotechnologies

«»

Links:  Standard Highlighted

Link to concordances are always highlighted on mouse hover

2.10.2. Nanotechnologies

 

Due to their diminutive size, nanoparticles exhibit properties that can differ substantially from those of matter in bulk or organized in larger particles. There are two main reasons for this. First, nanoparticles have, relatively, a larger surface area than the same mass of material produced in a larger bulk form. This can make materials more chemically reactive. Second, below 50 nm, the laws of classical physics give way to quantum effects, causing optical, electrical and magnetic behaviours different from those of the same material at a larger scale. These effects can give materials very useful physical properties such as exceptional electrical conduction or resistance, a high capacity for storing or transferring heat or different solubility properties.

 

Nanoparticles, whose dimensions range between 1 and 100 nm (0.001-0.1 μm), are characterized by specific properties. At the current stage of rapid evolution of nanoscience and nanotechnology it is not possible to be scientifically precise over inclusion and exclusion criteria for defining a substance as a nanomaterial. But some aspects are known to be of utmost importance for the classification (e.g. natural occurring vs. manufactured nanoparticles, the status of micelles/capsule and the number of dimensions in the Nan orange). Engineered nanoparticles are increasingly produced and used in industrial fields as electronics, sporting products, clothes, sunscreens, cosmetics, computer, aerospace and other fields  such as food packaging, food supplements, food and feed additives, animal health, veterinary drugs, pesticides and plant health.

 

The existing and/or foreseen nanoparticles applications in the medical field include molecular diagnostic, imaging, drug discovery and drug delivery and therapy, for biomarker discovery, and uses in oncology and cardiovascular medicine. Currently, there is a considerable effort at international level for the evaluation and prevention of the possible health and environmental risks (The Royal Society, 2004; NIOSH, 2006; Schulte et al, 2007; Nel et al, 2006; Medina et al, 2007).

 

The nanoparticles categories of main interest for biomedical and other uses include (Nel et al, 2006); (Medina et al, 2007).

 

-           Carbon nanoparticles: Fullerenes, with polygonal structure formed by 60 carbon atoms and surfaces with tissue-binding capacity. Carbon nanotubes, of large use, with a cylinder structure, a high electrical conductivity and a remarkable mechanical strength. They may be also used in biomedicine as drug carriers;

-           Ceramic nanoparticles: Inorganic particles, with porous surface that can act as a drug vehicle;

-           Liposomes: lipid-based nanoparticles, largely used in pharmaceutical and cosmetic industries for drug delivery;

-           Emulsions: oil-water mixtures, with droplet diameters in the nanoscale; surfactants maintain their shape. Used for skincare;

-           Quantum dots: Nanosized semiconductors (also named nanocrystals), which under stimulation can emit light of various colours. Used for cell imaging, in particular in cancer imaging:

-           Nanorods: nanoparticles with 1- 100 nm length, used in medicine as imaging and contrast agents;

-           Polymer nanoparticles: Water-soluble polymer-protein and polymer-drug conjugates. Polymer-drug conjugates may allow some tumour targeting; and

-           Metallic and supermagnetic nanoparticles: Iron-oxide nanoparticles (5-100 nm range) are used for selective magnetic bioseparations and as vectors of drugs, bioactive molecules and DNA, with an external magnetic field directing their progress towards the target tissue.

 

For Europe, data on the actual use and market presence of these products are very limited. Only the UK maintains a voluntary reporting scheme for engineered nanomaterials in general and only nine products have been reported so far (September 2007) 4. In the US, the Woodrow Wilson International Centre for Scholars has compiled an inventory of products which claim to contain nanotechnology products or be based on nanotechnology5.

 

 





4 See: http://www.defra.gov.uk/environment/nanotech/policy/index.htm.



5 See: http://www.nanotechproject. Org/44.